|
1
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Benson AB, Venook AP, Al-Hawary MM,
Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D,
Engstrom PF, et al: Rectal cancer, version 2.2018, NCCN Clinical
Practice Guidelines in Oncology. J Natl Compr Canc Netw.
16:874–901. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rödel C, Liersch T, Becker H, Fietkau R,
Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M,
Raab HR, et al: Preoperative chemoradiotherapy and postoperative
chemotherapy with fluorouracil and oxaliplatin versus fluorouracil
alone in locally advanced rectal cancer: Initial results of the
German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol.
13:679–687. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bryant CL, Lunniss PJ, Knowles CH, Thaha
MA and Chan CL: Anterior resection syndrome. Lancet Oncol.
13:e403–e408. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fazio VW, Zutshi M, Remzi FH, Parc Y,
Ruppert R, Fürst A, Celebrezze J Jr, Galanduik S, Orangio G, Hyman
N, et al: A randomized multicenter trial to compare long-term
functional outcome, quality of life, and complications of surgical
procedures for low rectal cancers. Ann Surg. 246:481–490. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Paun BC, Cassie S, MacLean AR, Dixon E and
Buie WD: Postoperative complications following surgery for rectal
cancer. Ann Surg. 251:807–818. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nahas SC, Rizkallah Nahas CS, Sparapan
Marques CF, Ribeiro U Jr, Cotti GC, Imperiale AR, Capareli FC, Chih
Chen AT, Hoff PM and Cecconello I: Pathologic complete response in
rectal cancer: Can we detect it? Lessons learned from a proposed
randomized trial of watch-and-wait treatment of rectal cancer. Dis
Colon Rectum. 59:255–263. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Habr-Gama A, Perez RO, Nadalin W, Sabbaga
J, Ribeiro U Jr, Silva e Sousa AH Jr, Campos FG, Kiss DR and
Gama-Rodrigues J: Operative versus nonoperative treatment for stage
0 distal rectal cancer following chemoradiation therapy: Long-term
results. Ann Surg. 240:711–717; discussion 717–718. 2004.PubMed/NCBI
|
|
9
|
van der Valk MJM, Hilling DE, Bastiaannet
E, Meershoek-Klein Kranenbarg E, Beets GL, Figueiredo NL, Habr-Gama
A, Perez RO, Renehan AG and van de Velde CJH; IWWD Consortium, :
Long-term outcomes of clinical complete responders after
neoadjuvant treatment for rectal cancer in the International Watch
& Wait Database (IWWD): An international multicentre registry
study. Lancet. 391:2537–2545. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Habr-Gama A, São Julião GP, Fernandez LM,
Vailati BB, Andrade A, Araújo SEA, Gama-Rodrigues J and Perez RO:
Achieving a complete clinical response After neoadjuvant
chemoradiation that does not require surgical resection: It may
take longer than you think! Dis Colon Rectum. 62:802–808. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yeom SS, Lee SY, Kim CH, Kim YJ, Nam TK
and Kim HR: The outcome of non-operative treatment for rectal
cancer patients who had been cCR after neoadjuvant
chemoradiotherapy. Asian J Surg. 42:2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Renehan AG, Malcomson L, Emsley R, Scott N
and O'Dwyer ST; OnCoRe project investigators, : Watch-and-wait
versus surgical resection for patients with rectal cancer-Authors'
reply. Lancet Oncol. 17:e134–e135. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kong JC, Guerra GR, Warrier SK, Ramsay RG
and Heriot AG: Outcome and salvage surgery following ‘watch and
wait’ for rectal cancer after neoadjuvant therapy: A systematic
review. Dis Colon Rectum. 60:335–345. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Malietzis G, Giacometti M, Askari A,
Nachiappan S, Kennedy RH, Faiz OD, Aziz O and Jenkins JT: A
preoperative neutrophil to lymphocyte ratio of 3 predicts
disease-free survival after curative elective colorectal cancer
surgery. Ann Surg. 260:287–292. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee DY, Hong SW, Chang YG, Lee WY and Lee
B: Clinical significance of preoperative inflammatory parameters in
gastric cancer patients. J Gastric Cancer. 13:111–116. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stotz M, Gerger A, Eisner F, Szkandera J,
Loibner H, Ress AL, Kornprat P, AlZoughbi W, Seggewies FS, Lackner
C, et al: Increased neutrophil-lymphocyte ratio is a poor
prognostic factor in patients with primary operable and inoperable
pancreatic cancer. Br J Cancer. 109:416–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pichler M, Hutterer GC, Stoeckigt C,
Chromecki TF, Stojakovic T, Golbeck S, Eberhard K, Gerger A,
Mannweiler S, Pummer K and Zigeuner R: Validation of the
pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in
a large European cohort of renal cell carcinoma patients. Br J
Cancer. 108:901–907. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Azab B, Shah N, Radbel J, Tan P, Bhatt V,
Vonfrolio S, Habeshy A, Picon A and Bloom S: Pretreatment
neutrophil/lymphocyte ratio is superior to platelet/lymphocyte
ratio as a predictor of long-term mortality in breast cancer
patients. Med Oncol. 30:4322013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yamada S, Fujii T, Yabusaki N, Murotani K,
Iwata N, Kanda M, Tanaka C, Nakayama G, Sugimoto H, Koike M, et al:
Clinical implication of inflammation-based prognostic score in
pancreatic cancer: Glasgow prognostic score is the most reliable
parameter. Medicine (Baltimore). 95:e35822016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li MX, Liu XM, Zhang XF, Zhang JF, Wang
WL, Zhu Y, Dong J, Cheng JW, Liu ZW, Ma L and Lv Y: Prognostic role
of neutrophil-to-lymphocyte ratio in colorectal cancer: A
systematic review and meta-analysis. Int J Cancer. 134:2403–2413.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Roxburgh CS, Salmond JM, Horgan PG, Oien
KA and McMillan DC: The relationship between the local and systemic
inflammatory responses and survival in patients undergoing curative
surgery for colon and rectal cancers. J Gastrointest Surg.
13:2011–2019. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Heo J, Oh YT, Noh OK, Chun M, Park JE and
Cho SR: Nodal tumor response according to the count of peripheral
blood lymphocyte subpopulations during preoperative
chemoradiotherapy in locally advanced rectal cancer. Radiat Oncol
J. 34:305–312. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee IH, Hwang S, Lee SJ, Kang BW, Baek D,
Kim HJ, Park SY, Park JS, Choi GS, Kim JC, et al: Systemic
inflammatory response after preoperative chemoradiotherapy can
affect oncologic outcomes in locally advanced rectal cancer.
Anticancer Res. 37:1459–1465. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Laird BJ, Fallon M, Hjermstad MJ, Tuck S,
Kaasa S, Klepstad P and McMillan DC: Quality of life in patients
with advanced cancer: Differential association with performance
status and systemic inflammatory response. J Clin Oncol.
34:2769–2775. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tong GJ, Zhang GY, Liu J, Zheng ZZ, Chen
Y, Niu PP and Xu X: Comparison of the eighth version of the
American Joint Committee on Cancer manual to the seventh version
for colorectal cancer: A retrospective review of our data. World J
Clin Oncol. 9:148–161. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gomez D, Morris-Stiff G, Toogood GJ, Lodge
JP and Prasad KR: Impact of systemic inflammation on outcome
following resection for intrahepatic cholangiocarcinoma. J Surg
Oncol. 97:513–518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ku JH, Kang M, Kim HS, Jeong CW, Kwak C
and Kim HH: The prognostic value of pretreatment of systemic
inflammatory responses in patients with urothelial carcinoma
undergoing radical cystectomy. Br J Cancer. 112:461–467. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shen L, Zhang H, Liang L, Li G, Fan M, Wu
Y, Zhu J and Zhang Z: Baseline neutrophil-lymphocyte ratio (≥2.8)
as a prognostic factor for patients with locally advanced rectal
cancer undergoing neoadjuvant chemoradiation. Radiat Oncol.
9:2952014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Braun LH, Baumann D, Zwirner K, Eipper E,
Hauth F, Peter A, Zips D and Gani C: Neutrophil-to-lymphocyte ratio
in rectal cancer-novel biomarker of tumor immunogenicity during
radiotherapy or confounding variable? Int J Mol Sci. 20:24482019.
View Article : Google Scholar
|
|
31
|
Dudani S, Marginean H, Tang PA, Monzon JG,
Raissouni S, Asmis TR, Goodwin RA, Gotfrit J, Cheung WY and Vickers
MM: Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as
predictive and prognostic markers in patients with locally advanced
rectal cancer treated with neoadjuvant chemoradiation. BMC Cancer.
19:6642019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Picardo SL, Teo M, Jalil KIA, Naqvi SY,
Morris PG, Breathnach OS, Grogan W, Leonard GD and Hennessy B:
Correlation between platelet/lymphocyte ratio,
neutrophil/lymphocyte ratio and response to neoadjuvant
chemoradiation therapy in rectal cancer. J Clin Oncol.
34:e151402016. View Article : Google Scholar
|
|
33
|
Shin US, You YN, Price BA, Rodriguez-Bigas
MA, Skibber JM, Maru DM, Taggart MW, Kopetz S, Eng C, Minsky BD, et
al: Is the neutrophil-lymphocyte ratio (NLR) a predictive and
prognostic factor in rectal cancer patients treated with
neoadjuvant chemoradiation (nCRT)? J Clin Oncol. 34:36052016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Deng Y, Chi P, Lan P, Wang L, Chen W, Cui
L, Chen D, Cao J, Wei H, Peng X, et al: Modified FOLFOX6 with or
without radiation versus fluorouracil and leucovorin with radiation
in neoadjuvant treatment of locally advanced rectal cancer: Initial
results of the Chinese FOWARC multicenter, open-label, randomized
three-arm phase III trial. J Clin Oncol. 34:3300–3307. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Allegra CJ, Yothers G, O'Connell MJ, Beart
RW, Wozniak TF, Pitot HC, Shields AF, Landry JC, Ryan DP, Arora A,
et al: Neoadjuvant 5-FU or capecitabine plus radiation with or
without oxaliplatin in rectal cancer patients: A phase III
randomized clinical trial. J Natl Cancer Inst. 107:djv2482015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Moureau-Zabotto L, Farnault B, de
Chaisemartin C, Esterni B, Lelong B, Viret F, Giovannini M, Monges
G, Delpero JR, Bories E, et al: Predictive factors of tumor
response after neoadjuvant chemoradiation for locally advanced
rectal cancer. Int J Radiat Oncol Biol Phys. 80:483–491. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kalady MF, de Campos-Lobato LF, Stocchi L,
Geisler DP, Dietz D, Lavery IC and Fazio VW: Predictive factors of
pathologic complete response after neoadjuvant chemoradiation for
rectal cancer. Ann Surg. 250:582–589. 2009.PubMed/NCBI
|
|
38
|
Burnette B, Fu YX and Weichselbaum RR: The
confluence of radiotherapy and immunotherapy. Front Oncol.
2:1432012. View Article : Google Scholar : PubMed/NCBI
|
